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Abstract 
The biophysical microenvironment of the tumor site has significant impact on breast cancer 
progression and metastasis.  The importance of altered mechanotransduction in cancerous tissue 
has been documented, yet its role in the regulation of cellular metabolism and the potential link 
between cellular energy and cell migration remain poorly understood. In this study, we 
investigated the role of mechanotransduction in AMP-activated protein kinase (AMPK) 
activation in breast cancer cells in response to interstitial fluid flow (IFF). Additionally, we 
explored the involvement of AMPK in breast cancer cell migration. IFF was applied to the 3D 
cell-matrix construct. The subcellular signaling activity of Src, FAK, and AMPK was visualized 
in real-time using fluorescent resonance energy transfer (FRET). We observed that breast cancer 
cells (MDA-MB-231) are more sensitive to IFF than normal epithelial cells (MCF-10A). AMPK 
was activated at the mitochondria of MDA-MB-231 cells by IFF, but not in other subcellular 
compartments (i.e., cytosol, plasma membrane, and nucleus). The inhibition of FAK or Src 
abolished flow-induced AMPK activation in the mitochondria of MDA-MB-231 cells. We also 
observed that global AMPK activation reduced MDA-MB-231 cell migration. Interestingly, 
specific AMPK inhibition in the mitochondria reduced cell migration and blocked flow-induced 
cell migration. Our results suggest the linkage of FAK/Src and mitochondria-specific AMPK in 
mechanotransduction and the differential role of AMPK in breast cancer cell migration 
depending on its subcellular compartment-specific activation.         
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1. Introduction 
The altered biophysical microenvironment of the tumor plays significant roles in cancer 
progression and metastasis. Malignant epithelial mammary cells form primary tumors out of 
mammary ducts and into the surrounding extracellular matrix (ECM). This process places 
unwanted pressure on its confined ECM and increases IFF, which in turn promotes cancer cell 
migration and invasion [1-3]. This IFF-induced cell migration is mediated by integrin-mediated 
mechanotransduction [3-8]. For example, flow-induced shear stress exerted on breast cancer 
cells results in β1-integrin activation [3, 6-9]. Signals initiated at these focal adhesions are then 
transduced into cells via activation of integrin-associated tyrosine kinases – namely, Src and 
FAK [7, 8, 10, 11]. They are both highly expressed in metastatic breast cancer cells and their 
inhibition has been reported to suppress cancer cell migration [6, 7, 10, 12, 13].  
 
AMPK is a serine/threonine protein kinase that regulates cellular energy homeostasis [14-17]. It 
senses the ratios of AMP /ATP and ADP/ATP. As the ratios increase, the amount of viable 
energy inside the cell drops and AMPK is activated. AMPK has been mainly considered a 
metabolic tumor suppressor. AMPK activity is diminished in breast cancer, and its activation in 
metastatic cancer cells inhibits cell growth and migration [14, 18]. The efficacy of clinical 
AMPK activators in preventing tumor progression and metastasis is attributed in part to the 
inhibition of cell migration [18]. In spite of AMPK downregulation in tumor cells, AMPK has 
garnered much attention for having dual functions in cancer. Several lines of evidence show that 
when AMPK is “on” it stimulates mitophagy and enhances the metabolic survival of cancer 
cells; however, AMPK activation also inhibits tumor growth and proliferation [16, 17]. When 
AMPK is “off” it enables unchecked cancer growth and proliferation, but the metabolic plasticity 
of cells is diminished [16, 17]. This paradoxical nature of AMPK in cancer has led to the 
hypothesis that different subcellular activation of AMPK might determine the AMPK’s final role 
in cancer [15, 17]. Indeed, there have been efforts to identify the role of compartmentalized 
AMPK signaling in response to pharmacological AMPK modulators [19-21]. While 
accumulating evidence shows that the biophysical microenvironment plays a crucial role in 
cancer cell metabolism [22], it is unclear whether the subcellular compartment-specific AMPK 
responds to the upstream biophysical cues and determines discrete downstream cellular 
processes that can have pro- or anti-tumorigenic roles in cancer.   
 
In this study, we employed genetically encoded biosensors to visualize Src and FAK as well as 
AMPK activities at the specific subcellular locations in response to IFF in the 3D collagen-
Matrigel matrices. The AMPK responses of MDA-MB-231 cells were compared with those of 
MCF-10A cells. We investigated the role of global AMPK as well as mitochondria-specific 
AMPK on flow-induced cell migration. The role of Src and FAK on mitochondria-specific 
AMPK activities under flow was also examined. 
 
2. Materials and Methods 
2.1 Biosensors and plasmids 
The FRET-based biosensors were used to observe subcellular activities of Src, FAK, and AMPK. 
The development and specificity of these biosensors were previously described [23-25]. The Src 
biosensor (Lyn-Src) consists of a cyan fluorescent protein (CFP), the SH2 domain from c-Src, a 
yellow fluorescent protein (YFP), and Src substrate peptide [23]. Similarly, the FAK biosensor 
(Lyn-FAK) is comprised of a CFP, SH2 domain, YFP, and FAK substrate peptide [24]. The 
AMPK biosensors consist of a CFP, an FHA1 binding domain, an AMPK substrate peptide, and 
a YFP variant (cpVE172) [25]. The subcellular compartment-specific AMPK biosensors 
employed here were Cyto-, PM-, Nuc-, and Mito-AMPK, specific to the cytosol, plasma 
membrane, nucleus, and mitochondria, respectively. An AMPK inhibitor peptide targeted to the 
mitochondria (mito-AIP) was used. The development and accuracy of mito-AIP was previously 
described [25].  
 
2.2 Chemical reagents 
PF573228 (Sigma, 1 μM) and PP2 (Sigma, 10μM) were used to inhibit FAK and Src, 
respectively. Compound C (Millipore Sigma, 5 μM) and A769662 (Tocris, 25 μM) were used as 
a global AMPK inhibitor and activator, respectively.  
 
2.3 Cell culture and transfection 
The human breast cancer cell line MDA-MB-231 and human mammary epithelial cell line MCF-
10A were used.  MDA-MB-231 cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM, Lonza) supplemented with 10% FBS (Gibco) and 1% penicillin/streptomycin (Lonza). 
MCF-10A cells were cultured in DMEM/F12 (Gibco) supplemented with 10% FBS (Gibco), 1% 
penicillin/streptomycin (Lonza), 200 ng/mL human recombinant EGF, 50 μg/mL hydrocortisone, 
and 20 μg/mL insulin (Sigma). All cells were maintained at 37 °C and 5% CO2 in a humidified 
incubator. For transfection, lipofectamine LTX (Invitrogen) was used following the 
manufacturer’s protocol.  Prior to experimentation, transfected cells were transferred to type I 
collagen-coated glass-bottom dishes (MatTek) or μ-slide cell culture chambers (Ibidi) and 
incubated for at least 2 hours. 
 2.4 Collagen-Matrigel preparation and characterization 
For 3D experiments, cells were seeded in type I collagen-Matrigel consisting of 1 part antibiotic-
free DMEM (10X), 8 parts PureCol type I collagen solution (Advanced BioMatrix, 3 mg/mL), 
and 1 part Matrigel (Corning, 9.8 mg/mL). The pH of the mixture was adjusted to 7.4 using 
sterile NaOH or HCl. The complete collagen-Matrigel solution was warmed to room 
temperature, and cells were suspended in the mixture at a density of 1×106 cells/mL. For 3D 
experiments, 100 μL of the mixture was added into a glass-bottom dish (MatTek) or injected into 
a μ-slide cell culture chamber (Ibidi). Cell-gel mixtures were incubated for 2 hours at 37 °C and 
5% CO2 to form gel. Once gelation was complete, low-serum (1% FBS), antibiotic-free DMEM 
was added to each dish or chamber, and the samples were incubated for at least 2 hours before 
imaging. The interstitial flow speed through the 3D collagen-Matrigel was calculated by 
measuring the intensity of fluorescent probes moving through the cell-gel construct over time 
[26]. Briefly, fluorescent images were taken of collagen gel inside the flow chamber before the 
addition of fluorescent probes, providing a reference for background intensity. Next, Alexa Fluor 
594-conjugated bovine serum albumin (BSA-594, Thermo Fisher, 50 μg/ml) was added to the 
FluoroBrite DMEM (Gibco) that perfused the flow chamber. Using the syringe pump, the 
fluorescent media was delivered through the gel construct at known volumetric flow rates (2, 5, 
10 μL/min). Fluorescent images were obtained every minute for 10 minutes to track the 
perfusion of BSA-594 through the collagen gel. This range of interstitial flow speed yields a 
corresponding range of fluid shear stress exerted on cells embedded in the collagen-Matrigel 
which was found to be 2-10 dyne/cm2 [26].  
 
2.5 Shear stress application 
Fluid flow-induced shear stress was applied to both 2D and 3D cell samples grown in μ-slide cell 
culture chambers (Ibidi). For 2D samples, unidirectional flow was applied with phenol red-free 
DMEM (HyClone) supplemented with 1% FBS using a peristaltic pump (Cole-Parmer). The 
shear stress of 10 dyne/cm2 was applied by controlling the flow rate of the pump.  The necessary 
flow rate was calculated according to the manufacture’s protocol. For 3D collagen gel samples, a 
unidirectional, pulsatile (0.2 Hz) flow was applied using a syringe pump (Harvard Apparatus) 
[26]. Three different flow rates (2, 5, 10 μL/min) were used to generate a range of shear stresses 
on the cells [26]. The flow chamber was connected to the syringe pump via sterile tubing filled 
with FluoroBrite DMEM (Gibco) with 1% FBS. Shear stress experiments were conducted at 
37 °C and 5% CO2 using a humidified incubation chamber (Ibidi). 
 
2.6 Random migration assay 
Cells were first incubated for 30 minutes with CellTracker Green CMFDA (Thermo Fisher, 20 
μM). Cells were then seeded at low (10-20%) confluency on μ-slide flow chambers (Ibidi) 
coated with type I collagen (Advanced Biomatrix, 100 μg/mL), and incubated for 2 hours. Flow 
chambers were then subjected to 0 or 10 dyne/cm2 for 8 hours. For some experiments, cells were 
treated with Compound C or A769662, or transfected with mito-AIP. Antibiotic-free, phenol red-
free DMEM (1% FBS) was used for all migration experiments. Flow chambers were kept at 
37 °C and 5% CO2 inside a humidified incubation chamber (Ibidi) during the migration assay. 
Imaging regions were selected to include multiple isolated cells, away from the chamber walls 
and free to migrate randomly [27].  
 
2.7 Microscopy and image analysis 
All images were captured using a Nikon Ti-E inverted microscope equipped with an Evolve 512 
EMCCD camera (Photometrics) and Perfect Focus System (Nikon). FRET images were acquired 
using CFP 438 excitation, CFP 483 emission, and YFP 542 emission wavelength filters. Green 
fluorescent images were captured using a GFP 522 emission wavelength filter. To reduce 
photobleaching, a neutral density (ND) 32 filter was used with the HG lamp (Nikon). For IFF 
experiments, FRET and DIC images were taken every 2 minutes for 1 hour using a 40× 
objective. FRET ratio images for Src, FAK, and AMPK biosensors were created using NIS-
Elements software (Nikon) and ImageJ [26]. For cell migration experiments, images of DIC and 
GFP were taken every 5 minutes for 8 hours using a 15× objective. Cell tracking was conducted 
using the ImageJ plugin TrackMate [28]. Isolated cells that stayed within the image frame, did 
not divide, and did not die during the 8 hours were selected. Average distance traveled was 
calculated in Excel (Microsoft).  
 
2.8 Statistical analysis 
Three independent experiments were conducted for each condition. All statistical data are shown 
as the mean ± standard error of the mean (SEM).  Statistical significance between multiple 
groups was determined using one-way analysis of variance (ANOVA) with Dunnett’s post hoc 
test. Statistical significance between two groups was assessed using Student’s t-test. All 
statistical analysis was completed using Prism 5 software (GraphPad). A p-value less than 0.05 
was considered statistically significant. 
 
3. Results 
3.1 IFF induces Mito-AMPK activity in MDA-MB-231 cells 
Since we hypothesized that subcellular compartment-specific AMPK might have distinct roles in 
cancer progression under flow, we first tested whether AMPK differently responds to IFF 
depending on the subcellular locations. The results revealed that only Mito-AMPK was 
significantly upregulated in response to 5 and 10 μL/min in MDA-MB-231 cells and the lowest 
flow rate (2 μL/min) did not significantly affect Mito-AMPK activity, suggesting the existence 
of the threshold for the flow-induced AMPK activity (Fig. 1A). Cyto-, PM-, and Nuc-AMPK 
were not activated by IFF in MDA-MB-231 cells. Next, we compared subcellular AMPK 
responses to IFF in cancer cells and normal cells. None of the biosensors displayed significant 
activation in MCF-10A cells (Fig. 1B). These data suggest that MDA-MB-231 cells and MCF-
10A cells might have different mechanosensitivity, and that AMPK at the mitochondria might 
have a distinct role in MDA-MB-231 cells under IFF.  
 
3.2 Inhibition of FAK or Src abolishes IFF-induced Mito-AMPK activity 
To determine the role of FAK and Src in AMPK activity, we first investigated the 
mechanotransduction of FAK and Src in MDA-MB-231 cells. Application of 10 μL/min IFF 
induced significant FAK activation, while 2 and 5 μL/min did not alter FAK (Fig. 2A). Src was 
also significantly activated by IFF in MDA-MB-231 cells. The 5 and 10 μL/min IFF activated 
Src with similar efficacy. Next, MDA-MB-231 cells transfected with Mito-AMPK were 
embedded in collagen-Matrigel and then incubated with either PF573228 or PP2. Both Src and 
FAK inhibition resulted in consistently lower Mito-AMPK activity compared to the untreated 
cells (Fig. 2B). Next, we sought to determine whether this inhibition could affect IFF-induced 
Mito-AMPK activity. The results revealed that inhibition of FAK or Src abolished IFF-induced 
Mito-AMPK activity, suggesting that FAK and Src are required for the flow-mediated 
mechanotransduction of AMPK at the mitochondria (Fig. 2C).  
 
3.3 Global AMPK activation reduces cancer cell migration 
To determine whether AMPK affects migratory behavior of MDA-MB-231 cells, we conducted 
a random migration assay. Results showed a significant decrease in cell migration in response to 
global AMPK activation (Fig. 3A). The average cell displacement for untreated cells was 158.0 
± 6.8 μm, while the average displacement for cells treated with A769662 was 104.0 ± 3.4 μm (a 
34% decrease). However, cells treated with Compound C did not show a significant difference in 
cell migration compared to the control. These results are consistent with published reports on the 
linkage of global AMPK activation and the decreased migration or invasion of many cancers, 
including breast cancer [14, 18]. 
 
3.4 Mitochondria-specific AMPK inhibition reduces cancer cell migration 
Since we observed that IFF increased AMPK activity at the mitochondria in MDA-MB-231 cells 
(Fig. 1), we sought to determine the role of mitochondria-specific AMPK in cancer cell 
migration. MDA-MB-231 cells transfected with mito-AIP showed significantly reduced cell 
migration although to a lesser degree compared to the A769662-treated cells (Fig. 3A). The 
average cell displacement for mito-AIP transfected cells was 136.0 ± 5.3 μm (14% decrease) 
compared to the control group (Fig. 3B). To ensure that decreased migration was not simply a 
result of transfection, cells transfected with a transfection reagent alone as well as a Mito-AMPK 
biosensor were compared with the control group. Transfection did not significantly affect cell 
migration (data not shown).  
 3.5 Mitochondria-specific AMPK inhibition blocks flow-induced cell migration 
To further investigate the role of AMPK activity at the mitochondria in cancer cell migration, we 
conducted a cell migration assay under flow conditions. MDA-MB-231 cells were plated in 
collagen-coated flow chambers and subjected to fluid flow at 10 dyne/cm2. Cells subjected to 8 
hours of fluid flow showed a significant increase in cell migration compared to the control group 
(Fig. 3A, B). This confirmed the notion that fluid shear stress increases cancer cell metastatic 
potential. Next, cells were transfected with mito-AIP and then subjected to 10 dyne/cm2 fluid 
flow. Mitochondria-specific AMPK inhibition abolished the migration response to fluid flow 
(Fig. 3A). The average cell displacement was reduced to 132.1 ± 6.9 μm, a 16.4% decrease 
compared to the control group (Fig. 3B). To test whether suppressed cell migration by mito-AIP 
is due to the effect of decreased AMPK activity at the mitochondria, we measured subcellular 
AMPK activity with and without mito-AIP treatment. Transfection with mito-AIP significantly 
increased cytosolic AMPK while decreasing mitochondria AMPK (Fig. 3C). This result is in line 
with the notion that AMPK at the mitochondria is primarily involved in ATP homeostasis 
through a feedback mechanism [25]. Taken together, these results suggest that cytosolic AMPK 
and mitochondrial AMPK might have a distinct, antagonistic role in breast cancer cell migration 
under flow. 
 
4. Discussion 
In this study we employed a 3D collagen-Matrigel model in conjunction with live cell imaging to 
visualize the activity of subcellular AMPK in response to IFF. We first examined subcellular 
compartment-specific AMPK activity under IFF in MDA-MB-231 cells and MCF-10A cells. 
Interestingly, AMPK at the mitochondria in MDA-MB-231 cells exhibited an immediate 
response to IFF, while none of the AMPK in MCF-10A cells was responsive to IFF. This is in 
line with the previous findings that cancer cells are sensitive to abnormal mechanical 
environments such as stiffer extracellular matrix stiffness and increased IFF [3, 22, 29]. The 
molecular mechanism of distinct AMPK response to IFF at the mitochondria is not clear, but one 
speculation would be that mitochondria is perturbed by extracellular mechanical stresses through 
the cytoskeleton [30]. A recent report also suggests that AMPK activation by mechanical stresses 
requires cytoskeleton-mediated intracellular contractility [31]. 
 
We identified AMPK at the mitochondria as a potential downstream target of FAK/Src signaling 
in response to IFF. FAK and Src play a primary role in integrin-dependent mechanotransduction 
in tumor tissues as well as many other tissues [32, 33]. We showed here that inhibition of FAK 
or Src suppressed the basal activation level of Mito-AMPK and blocked IFF-induced Mito-
AMPK activation. To our knowledge, this is the first report that describes the involvement of 
FAK and Src in the mechanotransduction of mitochondria-specific AMPK. AMPK has been 
shown to mediate integrin β1 [34] as well as FAK [35]. On the contrary, AMPK is mediated 
through Src [36, 37]. Together with these data, our results suggest that there might be a feedback 
loop in mechanotransduction between FAK/Src and AMPK.  
 
Our data also highlight the importance of AMPK at the mitochondria in cell migration. 
Mitochondria regulate calcium homeostasis needed for polarity and cell migration and MDA-
MB-231 cells cannot migrate effectively when mitochondrial genes are perturbed [38]. During 
cell migration, mitochondria reposition strategically along microtubules, which polymerize 
toward cellular extensions [38-40]. AMPK controls the speed of microtubule polymerization 
toward focal adhesions [40], and AMPK activation localizes at the mitochondria as they were 
trafficked toward the leading edge of cells during migration [39]. Several lines of evidence 
including our data in the present study indicate that global AMPK activation reduces cell 
migration [14, 18]. We observed here that inhibition of AMPK at the mitochondria increased the 
activation level of cytosolic AMPK in MDA-MB-231 cells, which might negatively affect cell 
migration. In conclusion, our results suggest that localized AMPK activities at various 
subcellular domains may have unique or even antagonistic functions, particularly in MDA-MB-
231 cells.   
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Figure legends 
Figure 1. AMPK activities at subcellular compartments in response to IFF. FRET ratio images 
were scaled according to the color bar. IFF was applied at time = 0 min. (A) MDA-MB-231 
cells. Cyto-AMPK: n=13, 16, 11 (2, 5, 10 μL/min, respectively); Mito-AMPK: n=12, 14, 13 (2, 
5, 10 μL/min, respectively); PM-AMPK: n=11, 11, 12 (2, 5, 10 μL/min, respectively); Nuc-
AMPK: n=14, 12, 16 (2, 5, 10 μL/min, respectively). (B) MCF-10A cells. Cyto-AMPK: n=12, 
10, 20 (2, 5, 10 μL/min, respectively); Mito-AMPK: n=13, 13, 13 (2, 5, 10 μL/min, 
respectively); PM-AMPK: n=14, 14, 14 (2, 5, 10 μL/min, respectively); Nuc-AMPK: n=16, 14, 
14 (2, 5, 10 μL/min, respectively). Scale bars, 10 μm. * p<0.05. 
 
Figure 2. Involvement of FAK and Src in Mito-AMPK activity. Scale bars, 10 μm. (A) FAK and 
Src activity in MDA-MB-231 cells under IFF. FAK: n=10, 8, 8 (2, 5, 10 μL/min, respectively). 
Src: n=9, 9, 8 (2, 5, 10 μL/min, respectively). (B) Mito-AMPK basal activity in MDA-MB-231 
cells after treatment with PF573228 or PP2. n>13. ** p<0.01, *** p<0.001. (C) Mito-AMPK 
response to IFF in MDA-MB-231 cells pre-treated with PF573228 or PP2. n>14. 
 Figure 3. Cell migration is uniquely influenced by subcellular AMPK. (A) Cell trajectories. For 
visual comparison, the trajectories of 25 randomly selected cells are shown. (B) Average 
displacement of cells over 8 hours. Control, n=30; A769962, n=54; Compound C, n=64; mito-
AIP, n=36; fluid flow, n=41; fluid flow + mito-AIP, n=39. (C) Subcellular compartment-specific 
AMPK activities in response to mito-AIP. n>20. * p<0.05. *** p<0.001. 
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